Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Status:
Terminated
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of
Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and
Type 2 diabetes mellitus (T2DM).